<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207934</url>
  </required_header>
  <id_info>
    <org_study_id>98-0643</org_study_id>
    <nct_id>NCT01207934</nct_id>
  </id_info>
  <brief_title>Recombinant Human Leptin Therapy Effects on Insulin Action</brief_title>
  <acronym>Leptin</acronym>
  <official_title>Recombinant Human Leptin Therapy Effects on Insulin Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leptin therapy improves insulin sensitivity in people with leptin-deficiency but it is not
      known whether it improves insulin action in persons who are not leptin deficient. The purpose
      of the present study was to determine whether leptin therapy has effects on insulin action in
      obese subjects with type 2 diabetes mellitus (T2DM). A randomized, placebo controlled trial
      was conducted in obese subjects with newly-diagnosed T2DM. Subjects were randomized to
      treatment with placebo, low-dose, or high-dose leptin. Insulin sensitivity was measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leptin therapy improves insulin sensitivity in people with leptin-deficiency but it is not
      known whether it improves insulin action in persons who are not leptin deficient. The purpose
      of the present study was to determine whether leptin therapy has weight loss-independent
      effects on insulin action in obese subjects with type 2 diabetes mellitus (T2DM). A
      randomized, placebo controlled trial was conducted in obese subjects with newly-diagnosed
      T2DM. Subjects were randomized to treatment with placebo (saline), low-dose (30 mg/d), or
      high-dose (80 mg/d) recombinant methionyl human (r-met hu) leptin for 14 days. Multi-organ
      insulin sensitivity before and after treatment was evaluated by using the
      hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopically labelled
      tracer infusions to measure glucose, glycerol and fatty acid kinetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars.</measure>
    <time_frame>baseline</time_frame>
    <description>pre-treatment glucose disposal. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.</measure>
    <time_frame>fourteen days</time_frame>
    <description>This is a measure of the body's ability to metabolize sugar after treatment with either leptin or a placebo. We compare the effect of leptin therapy on insulin-mediated stimulation of glucose disposal with that of placebo. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Plasma Leptin Concentrations</measure>
    <time_frame>baseline</time_frame>
    <description>Leptin is an endogenous hormone. Here we measure the pre-treatment concentration of naturally-occurring leptin in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Plasma Leptin Levels</measure>
    <time_frame>fourteen days</time_frame>
    <description>plasma leptin levels after fourteen days ingestion of either leptin or placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Type Two Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline placebo for fourteen days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low-dose leptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose leptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose leptin</intervention_name>
    <description>30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
    <arm_group_label>low-dose leptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose leptin</intervention_name>
    <description>80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
    <arm_group_label>high-dose leptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with type 2 diabetes for less than ten years

          -  Body mass index 25 - 40

          -  hemoglobin A1C 7.5% - 12.0%

          -  fasting blood glucose between 90 and 240mg/dL

        Exclusion Criteria:

          -  smoking

          -  pregnancy

          -  diabetes medications

          -  regular exercise (more than 3 hours per week)

          -  uncontrolled hypertension: systolic blood pressure greater than 160 or diastolic blood
             pressure greater than 95
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <results_first_submitted>June 6, 2011</results_first_submitted>
  <results_first_submitted_qc>July 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2011</results_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from August 1998 to August 1999. All subjects were recruited via the Volunteer for Health system at Washington University School of Medicine.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>saline placebo for fourteen days</description>
        </group>
        <group group_id="P2">
          <title>Low-dose Leptin</title>
          <description>30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
        </group>
        <group group_id="P3">
          <title>High-dose Leptin</title>
          <description>80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>saline placebo for fourteen days</description>
        </group>
        <group group_id="B2">
          <title>Low-dose Leptin</title>
          <description>30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
        </group>
        <group group_id="B3">
          <title>High-dose Leptin</title>
          <description>80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="1.2"/>
                    <measurement group_id="B2" value="53" spread="2.9"/>
                    <measurement group_id="B3" value="54" spread="1.6"/>
                    <measurement group_id="B4" value="56" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars.</title>
        <description>pre-treatment glucose disposal. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>14 days on placebo (saline)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Leptin</title>
            <description>30mg leptin daily for fourteen days</description>
          </group>
          <group group_id="O3">
            <title>High Dose Leptin</title>
            <description>80mg leptin daily for fourteen days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars.</title>
          <description>pre-treatment glucose disposal. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight.</description>
          <units>mmol/kg body weight/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="3.1"/>
                    <measurement group_id="O2" value="18.4" spread="3.6"/>
                    <measurement group_id="O3" value="16.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Plasma Leptin Concentrations</title>
        <description>Leptin is an endogenous hormone. Here we measure the pre-treatment concentration of naturally-occurring leptin in the blood.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>14 days on placebo (saline)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Leptin</title>
            <description>30mg leptin daily for fourteen days</description>
          </group>
          <group group_id="O3">
            <title>High Dose Leptin</title>
            <description>80mg leptin daily for fourteen days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Plasma Leptin Concentrations</title>
          <description>Leptin is an endogenous hormone. Here we measure the pre-treatment concentration of naturally-occurring leptin in the blood.</description>
          <units>Micrograms/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="7"/>
                    <measurement group_id="O2" value="24" spread="8"/>
                    <measurement group_id="O3" value="35" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.</title>
        <description>This is a measure of the body's ability to metabolize sugar after treatment with either leptin or a placebo. We compare the effect of leptin therapy on insulin-mediated stimulation of glucose disposal with that of placebo. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight.</description>
        <time_frame>fourteen days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>14 days on placebo (saline)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Leptin</title>
            <description>30mg leptin daily for fourteen days</description>
          </group>
          <group group_id="O3">
            <title>High Dose Leptin</title>
            <description>80mg leptin daily for fourteen days</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.</title>
          <description>This is a measure of the body's ability to metabolize sugar after treatment with either leptin or a placebo. We compare the effect of leptin therapy on insulin-mediated stimulation of glucose disposal with that of placebo. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight.</description>
          <units>mmol/kg body weight/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="2.5"/>
                    <measurement group_id="O2" value="20.7" spread="3.0"/>
                    <measurement group_id="O3" value="19.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there would be no change in glucose disposal between the three groups (placebo, low dose leptin, and high dose leptin). Power calculations were done showing that 6 subjects in each arm was enough to detect a 35% between group difference in glucose disposal at the 0.05 level with 80% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>ANOVA for reapeated measures was used to compare the three groups.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Plasma Leptin Levels</title>
        <description>plasma leptin levels after fourteen days ingestion of either leptin or placebo.</description>
        <time_frame>fourteen days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>14 days on placebo (saline)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Leptin</title>
            <description>30mg leptin daily for fourteen days</description>
          </group>
          <group group_id="O3">
            <title>High Dose Leptin</title>
            <description>80mg leptin daily for fourteen days</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Plasma Leptin Levels</title>
          <description>plasma leptin levels after fourteen days ingestion of either leptin or placebo.</description>
          <units>Micrograms/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="5"/>
                    <measurement group_id="O2" value="76" spread="19"/>
                    <measurement group_id="O3" value="5024" spread="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that treatment would not effect plasma leptin levels.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>a priori threshold for significance was set at p = 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>T-tests compared pre and post-treatment values.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>null hypothesis was that plasma leptin levels would be equal after treatment in the placebo and high-dose leptin groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>a priori threshold for significance was p = 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>saline placebo for fourteen days</description>
        </group>
        <group group_id="E2">
          <title>Low-dose Leptin</title>
          <description>30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
        </group>
        <group group_id="E3">
          <title>High-dose Leptin</title>
          <description>80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samuel Klein, MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>3143628708</phone>
      <email>sklein@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

